[HTML][HTML] Doxorubicin induced heart failure: Phenotype and molecular mechanisms
MA Mitry, JG Edwards - IJC heart & vasculature, 2016 - Elsevier
Long term survival of childhood cancers is now more than 70%. Anthracyclines, including
doxorubicin, are some of the most efficacious anticancer drugs available. However, its use …
doxorubicin, are some of the most efficacious anticancer drugs available. However, its use …
[HTML][HTML] Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival
F Miglietta, M Bottosso, G Griguolo, MV Dieci… - ESMO open, 2022 - Elsevier
Highlights•The treatment landscape of MBC has progressively widened in the last
years.•Several therapeutic strategies proved to be capable of prolonging survival of patients …
years.•Several therapeutic strategies proved to be capable of prolonging survival of patients …
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Background The poly (adenosine diphosphate–ribose) inhibitor talazoparib has shown
antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 …
antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 …
Emerging role of PARP inhibitors in metastatic triple negative breast cancer. Current scenario and future perspectives
G Barchiesi, M Roberto, M Verrico, P Vici… - Frontiers in …, 2021 - frontiersin.org
Triple negative tumors represent 15% of breast cancer and are characterized by the lack of
estrogen receptors, progesterone receptor, and HER2 amplification or overexpression …
estrogen receptors, progesterone receptor, and HER2 amplification or overexpression …
Therapeutic applications of PARP inhibitors: anticancer therapy and beyond
The aim of this article is to describe the current and potential clinical translation of
pharmacological inhibitors of poly (ADP-ribose) polymerase (PARP) for the therapy of …
pharmacological inhibitors of poly (ADP-ribose) polymerase (PARP) for the therapy of …
[PDF][PDF] BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies
C Albert, M Haase, A Albert, S Kropf… - Annals of laboratory …, 2020 - synapse.koreamed.org
Background The ability of urinary biomarkers to complement established clinical risk
prediction models for postoperative adverse kidney events is unclear. We assessed the …
prediction models for postoperative adverse kidney events is unclear. We assessed the …
Poly (ADP-Ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond
S Boussios, C Abson, M Moschetta, E Rassy… - Drugs in R&D, 2020 - Springer
Genetic complexity and DNA damage repair defects are common in different cancer types
and can induce tumor-specific vulnerabilities. Poly (ADP-ribose) polymerase (PARP) …
and can induce tumor-specific vulnerabilities. Poly (ADP-ribose) polymerase (PARP) …
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations …
Purpose: To assess talazoparib activity in germline BRCA1/2 mutation carriers with
advanced breast cancer. Patients and Methods: ABRAZO (NCT02034916) was a two-cohort …
advanced breast cancer. Patients and Methods: ABRAZO (NCT02034916) was a two-cohort …
Crosstalk between poly (ADP-ribose) polymerase and sirtuin enzymes
Abstract Poly (ADP-ribose) polymerases (PARPs) are NAD+ dependent enzymes that were
identified as DNA repair proteins, however, today it seems clear that PARPs are responsible …
identified as DNA repair proteins, however, today it seems clear that PARPs are responsible …